LIVIVO - Search results -

Search results

Result 1 - 10 of total 44

Search options

Article ; Online: Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.

Saraiva, José Francisco Kerr / Franco, Denise

2021 Volume 20, Issue 1, Page(s) 235

Abstract: Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, ... ...

Abstract	Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, controls blood glucose and results in significant body weight loss in patients with type 2 diabetes. Beyond these well-known effects, an interesting aspect of this drug is its antiatherogenic activity, which should be further explored in clinical practice. This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drug's antiatherosclerotic properties. The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids. Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management.
MeSH term(s)	Administration, Oral ; Animals ; Atherosclerosis/diagnosis ; Atherosclerosis/drug therapy ; Atherosclerosis/mortality ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cause of Death ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/mortality ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Glycemic Control/adverse effects ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Incretins/administration & dosage ; Incretins/adverse effects ; Risk Assessment ; Risk Factors ; Treatment Outcome
Chemical Substances	Biomarkers ; Blood Glucose ; GLP1R protein, human ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Incretins ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8)
Language	English
Publishing date	2021-12-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2093769-6
ISSN	1475-2840 ; 1475-2840
ISSN (online)	1475-2840
ISSN	1475-2840
DOI	10.1186/s12933-021-01417-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.

Saraiva, José Francisco Kerr

Cardiology and therapy

2018 Volume 7, Issue 1, Page(s) 15–24

Abstract: Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non- ... ...

Abstract	Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran (a direct thrombin inhibitor) and apixaban, edoxaban, and rivaroxaban (factor Xa inhibitors) are not only non-inferior or superior to warfarin but also demonstrate a decreased risk of cerebrovascular bleeding among patients with AF and moderate to high risk of stroke. Additionally, NOACs have an advantage of requiring no monitoring of the international normalized ratio compared with warfarin. This review summarizes the published literature on NOACs for the primary and secondary prevention of ischemic strokes, with an emphasis on the expected absolute benefits from the introduction of such agents. As compared with warfarin, NOACs significantly reduce the risk of hemorrhagic stroke, and only dabigatran (150 mg twice daily) was found to significantly reduce the risk of ischemic stroke. However, measures of relative benefits from medical interventions do not immediately provide the estimated benefit to be derived from an individual patient, something best done by considering the expected absolute benefit. The number needed to treat (NNT) is presented for various outcomes in the phase 3 trials of NOACs. Despite the important progress achieved with the introduction of NOACs, the availability of at least four agents with different efficacy and safety performances in comparison with warfarin prompts the question of whether any of these agents is preferable to another. It is hoped that future studies on the efficacy, safety, and economic performance of NOACs will further allow for rational choices within this important therapeutic class. Meanwhile, the NNT may be a valid metric to be considered by clinicians faced with the need to make such choices.
Language	English
Publishing date	2018-02-27
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2700626-8
ISSN	2193-6544 ; 2193-8261
ISSN (online)	2193-6544
ISSN	2193-8261
DOI	10.1007/s40119-018-0106-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA).

Précoma, Dalton Bertolim / Silva, Rafael Paletta da / Nakamoto, Allyson / Omar, Viviane Mariz / Lopes, Danilo / Saraiva, José Francisco Kerr

Arquivos brasileiros de cardiologia

2024 Volume 121, Issue 3, Page(s) e20230392

Abstract: Background: Clinical trials showed the safety of Edoxaban, a non-vitamin K-dependent oral anticoagulant (NOAC), and its efficacy to prevent stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients and also to prevent and treat ... ...

Title translation	Desenho de Estudo de um Estudo Observacional Brasileiro sobre o uso de Edoxabana em Pacientes com Fibrilação Atrial (EdoBRA).
Abstract	Background: Clinical trials showed the safety of Edoxaban, a non-vitamin K-dependent oral anticoagulant (NOAC), and its efficacy to prevent stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients and also to prevent and treat venous thromboembolism. However, additional research is needed to evaluate the safety and effectiveness of Edoxaban in a real-world scenario in the Brazilian population. Objective: In order to understand the risks and benefits of Edoxaban use in routine clinical settings, the EdoBRA study is being conducted to gain insight into the safety and effectiveness of Edoxaban use in non-preselected patients with NVAF in Brazil. Methods: The EdoBRA study is a multicenter, prospective, observational study conducted in 36 sites in Brazil. NVAF patients ≥ 18 years treated with commercially available Edoxaban who initiated treatment for at least 14 days and no longer than 90 days prior to enrollment, and who are not simultaneously participating in any interventional study are eligible for this study. Seven hundred patients are planned to be enrolled and one-year of follow up, with data collections expected at baseline and 3, 6, and 12 months after the study enrollment. The primary safety objective is ISTH Clinically Relevant Bleeding, and the secondary effectiveness objective focuses on relevant cardiovascular outcomes related to NVAF. Conclusion: EdoBRA observational study will generate relevant additional information about NOAC Edoxaban on various aspects of patient management in routine care, such as its safety and effectiveness profile in patients with NVAF in Brazil.
MeSH term(s)	Humans ; Atrial Fibrillation/drug therapy ; Thiazoles/therapeutic use ; Pyridines/therapeutic use ; Pyridines/adverse effects ; Prospective Studies ; Factor Xa Inhibitors/therapeutic use ; Brazil ; Stroke/prevention & control ; Research Design ; Time Factors ; Treatment Outcome ; Hemorrhage/chemically induced ; Anticoagulants/therapeutic use ; Anticoagulants/administration & dosage
Chemical Substances	edoxaban (NDU3J18APO) ; Thiazoles ; Pyridines ; Factor Xa Inhibitors ; Anticoagulants
Language	English
Publishing date	2024-04-26
Publishing country	Brazil
Document type	Journal Article ; Observational Study ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	730261-7
ISSN	1678-4170 ; 0066-782X
ISSN (online)	1678-4170
ISSN	0066-782X
DOI	10.36660/abc.20230392
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 548: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Physically Active Lifestyle as an Approach to Confronting COVID-19.

Ferreira, Maycon Junior / Irigoyen, Maria Cláudia / Consolim-Colombo, Fernanda / Saraiva, José Francisco Kerr / Angelis, Kátia De

Arquivos brasileiros de cardiologia

2020 Volume 114, Issue 4, Page(s) 601–602

Title translation	Vida Fisicamente Ativa como Medida de Enfrentamento ao COVID-19.
MeSH term(s)	Betacoronavirus ; COVID-19 ; Coronavirus Infections/prevention & control ; Exercise ; Humans ; Life Style ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; SARS-CoV-2
Keywords	covid19
Language	Portuguese
Publishing date	2020-04-09
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	730261-7
ISSN	1678-4170 ; 0066-782X
ISSN (online)	1678-4170
ISSN	0066-782X
DOI	10.36660/abc.20200235
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 548: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19, Renin-Angiotensin System, Angiotensin-Converting Enzyme 2, and Nicotine: What is the Interrelation?

Scholz, Jaqueline Ribeiro / Lopes, Marcelo Antônio Cartaxo Queiroga / Saraiva, José Francisco Kerr / Colombo, Fernanda Consolim

Arquivos brasileiros de cardiologia

2020 Volume 115, Issue 4, Page(s) 708–711

Title translation	COVID-19, Sistema Renina-Angiotensina, Enzima Conversora da Angiotensina 2 e Nicotina: Qual a Inter-Relação?
MeSH term(s)	Angiotensin-Converting Enzyme 2 ; Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Nicotine/adverse effects ; Pandemics ; Peptidyl-Dipeptidase A/genetics ; Pneumonia, Viral ; Renin-Angiotensin System ; SARS-CoV-2
Chemical Substances	Nicotine (6M3C89ZY6R) ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
Keywords	covid19
Language	Portuguese
Publishing date	2020-10-27
Publishing country	Brazil
Document type	Letter
ZDB-ID	730261-7
ISSN	1678-4170 ; 0066-782X
ISSN (online)	1678-4170
ISSN	0066-782X
DOI	10.36660/abc.20200653
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 548: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Vida Fisicamente Ativa como Medida de Enfrentamento ao COVID-19

Ferreira, Maycon Junior / Irigoyen, Maria Cláudia / Consolim-Colombo, Fernanda / Saraiva, José Francisco Kerr / Angelis, Kátia De

Arquivos Brasileiros de Cardiologia v.114 n.4 2020

2020

Keywords	Coronavirus-19 ; COVID-19 ; Exercício ; Atividade Motora ; Sedentarismo ; Fatores de Risco ; Prevenção e Controle ; covid19
Language	Portuguese
Publishing date	2020-04-01
Publisher	Sociedade Brasileira de Cardiologia - SBC
Publishing country	br
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Vida Fisicamente Ativa como Medida de Enfrentamento ao COVID-19

Ferreira, Maycon Junior / Irigoyen, Maria Cláudia / Consolim-Colombo, Fernanda / Saraiva, José Francisco Kerr / Angelis, Kátia De

Arquivos Brasileiros de Cardiologia n.ahead 2020

2020

Keywords	Coronavirus-19 ; COVID-19 ; Exercício ; Atividade Motora ; Sedentarismo ; Fatores de Risco ; Prevenção e Controle ; covid19
Language	Portuguese
Publishing date	2020-01-01
Publisher	Sociedade Brasileira de Cardiologia - SBC
Publishing country	br
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: COVID-19, Sistema Renina-Angiotensina, Enzima Conversora da Angiotensina 2 e Nicotina

Scholz, Jaqueline Ribeiro / Lopes, Marcelo Antônio Cartaxo Queiroga / Saraiva, José Francisco Kerr / Colombo, Fernanda Consolim

Arquivos Brasileiros de Cardiologia v.115 n.4 2020

Qual a Inter-Relação?

2020

Keywords	COVID-19 ; Coronavirus/complicações ; Betacoronavirus ; SARS-CoV2 ; Syndrome Respiratory Acute ; covid19
Language	Portuguese
Publishing date	2020-10-01
Publisher	Sociedade Brasileira de Cardiologia - SBC
Publishing country	br
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Sposito, Andrei C / Berwanger, Otávio / de Carvalho, Luiz Sérgio F / Saraiva, José Francisco Kerr

Cardiovascular diabetology

2019 Volume 18, Issue 1, Page(s) 23

Abstract: Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular ... ...

Abstract	Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes.
Language	English
Publishing date	2019-03-01
Publishing country	England
Document type	Journal Article ; Published Erratum
ISSN	1475-2840
ISSN (online)	1475-2840
DOI	10.1186/s12933-019-0825-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.

Ely, E Wesley / Ramanan, Athimalaipet V / Kartman, Cynthia E / de Bono, Stephanie / Liao, Ran / Piruzeli, Maria Lucia B / Goldman, Jason D / Saraiva, José Francisco Kerr / Chakladar, Sujatro / Marconi, Vincent C

The Lancet. Respiratory medicine

2022 Volume 10, Issue 4, Page(s) 327–336

Abstract: Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of ... ...

Abstract	Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. Methods: This exploratory trial followed the study design of COV-BARRIER in a critically ill cohort not included in the main phase 3 trial. The study was conducted across 18 hospitals in Argentina, Brazil, Mexico, and the USA. Participants (aged ≥18 years) hospitalised with laboratory-confirmed SARS-CoV-2 infection on baseline invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly assigned (1:1) to baricitinib (4 mg) or placebo once daily for up to 14 days in combination with standard of care. Participants, study staff, and investigators were masked to study group assignment. Prespecified endpoints included all-cause mortality through days 28 and 60, number of ventilator-free days, duration of hospitalisation, and time to recovery through day 28. The efficacy analysis was done in the intention-to-treat population and the safety analysis was done in the safety population. This trial is registered with ClinicalTrials.gov, NCT04421027. Findings: Between Dec 23, 2020, and April 10, 2021, 101 participants were enrolled into the exploratory trial and assigned to baricitinib (n=51) or placebo (n=50) plus standard of care. Standard of care included baseline systemic corticosteroid use in 87 (86%) participants. Treatment with baricitinib significantly reduced 28-day all-cause mortality compared with placebo (20 [39%] of 51 participants died in the baricitinib group vs 29 [58%] of 50 in the placebo group; hazard ratio [HR] 0·54 [95% CI 0·31-0·96]; p=0·030; 46% relative reduction; absolute risk reduction 19%). A significant reduction in 60-day mortality was also observed in the baricitinib group compared with the placebo group (23 [45%] events vs 31 [62%]; HR 0·56 [95% CI 0·33-0·97]; p=0·027; 44% relative reduction; absolute risk reduction 17%). In every six baricitinib-treated participants, one additional death was prevented compared with placebo at days 28 and 60. The number of ventilator-free days did not differ significantly between treatment groups (mean 8·1 days [SD 10·2] in the baricitinib group vs 5·5 days [8·4] in the placebo group; p=0·21). The mean duration of hospitalisation in baricitinib-treated participants was not significantly shorter than in placebo-treated participants (23·7 days [SD 7·1] vs 26·1 days [3·9]; p=0·050). The rates of infections, blood clots, and adverse cardiovascular events were similar between treatment groups. Interpretation: In critically ill hospitalised patients with COVID-19 who were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) reduced mortality, which is consistent with the mortality reduction observed in less severely ill patients in the hospitalised primary COV-BARRIER study population. However, this was an exploratory trial with a relatively small sample size; therefore, further phase 3 trials are needed to confirm these findings. Funding: Eli Lilly and Company.
MeSH term(s)	Adolescent ; Adult ; Azetidines ; COVID-19/drug therapy ; Critical Illness ; Double-Blind Method ; Extracorporeal Membrane Oxygenation ; Humans ; Purines ; Pyrazoles ; Respiration, Artificial ; SARS-CoV-2 ; Standard of Care ; Sulfonamides ; Treatment Outcome
Chemical Substances	Azetidines ; Purines ; Pyrazoles ; Sulfonamides ; baricitinib (ISP4442I3Y)
Language	English
Publishing date	2022-02-03
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2686754-0
ISSN	2213-2619 ; 2213-2600
ISSN (online)	2213-2619
ISSN	2213-2600
DOI	10.1016/S2213-2600(22)00006-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 7041: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito